| First Author | Morris M | Year | 2011 |
| Journal | PLoS One | Volume | 6 |
| Issue | 12 | Pages | e29257 |
| PubMed ID | 22206005 | Mgi Jnum | J:182343 |
| Mgi Id | MGI:5315240 | Doi | 10.1371/journal.pone.0029257 |
| Citation | Morris M, et al. (2011) Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One 6(12):e29257 |
| abstractText | Many neurodegenerative diseases are increasing in prevalence and cannot be prevented or cured. If they shared common pathogenic mechanisms, treatments targeting such mechanisms might be of benefit in multiple conditions. The tau protein has been implicated in the pathogenesis of diverse neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). Tau reduction prevents cognitive deficits, behavioral abnormalities and other pathological changes in multiple AD mouse models. Here we examined whether tau reduction also prevents motor deficits and pathological alterations in two mouse models of PD, generated by unilateral striatal injection of 6-hydroxydopamine (6-OHDA) or transgene-mediated neuronal expression of human wildtype alpha-synuclein. Both models were evaluated on Tau(+/+), Tau(+/-) and Tau(-/-) backgrounds in a variety of motor tests. Tau reduction did not prevent motor deficits caused by 6-OHDA and slightly worsened one of them. Tau reduction also did not prevent 6-OHDA-induced loss of dopaminergic terminals in the striatum. Similarly, tau reduction did not prevent motor deficits in alpha-synuclein transgenic mice. Our results suggest that tau has distinct roles in the pathogeneses of AD and PD and that tau reduction may not be of benefit in the latter condition. |
